ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer - EurekAlert

- May 30, 2019

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer EurekAlert

Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on ...

Search This Blog

Lung Cancer

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer - EurekAlert

Comments

Post a Comment

Popular posts from this blog

Beagles, other dogs could be used to help in early detection of lung cancers, study finds - Fox 32 Chicago

Not An Ordinary Cough: Lung Cancer Symptoms That You Might Neglect - International Business Times

Beagles, other dogs could be used to help in early detection of lung cancers, study finds - Fox 32 Chicago